EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Engineering the Future of Pneumococcal Conjugate Vaccines (PCV)
PhD, Chemical and Biotechnology, Savitribai Phule Pune University. Manager-Manufacturing, Inventprise Inc
Walmik Karbhari Gaikwad PhD is a seasoned biopharmaceutical expert with years in vaccine RD and manufacturing His PhD research pioneered costeffective processes for pneumococcal conjugate vaccines holds scholarly publications international patents and serves on editorial boards Based in Seattle currently works on cGMPcompliant process development and production at Inventprise Inc
Articles
Use of Steroids in COVID-19 patients
COVID is already declared as pandemic by World Health Organization and various new strains are also emergning across the globe and creating havoc Vaccines are developed and showing a promising results in the prevention of this infection The role of vaccine against new strains is complelty unclear so far Further till now no specific drug
Research Insights
Validation Of A Liquid Chromatographic Method For The Pharmaceutical Quality Control Of Products Containing Elacridar
Abstract Many anticancer drugs have an impaired bioavailability and poor brain penetration because they are substrates to drug efflux pumps such as Pglycoprotein and Breast Cancer Resistance Protein Elacridar is a strong inhibitor of these two drug efflux pumps and therefore has great potential to improve oral absorption and brain penetration of many anticanc
Case Studies
Open Innovation in Pharmaceutical Industry: A Case Study by Eli Lilly
Abstract Interest on Open Innovation paradigm has seen a phenomenal increase since last two decades especially when Henry Chesbrough coined this term in triggering the creation of a new whole body of knowledge However all of his research work could not come up with a standardized allinone theory Instead we find a heterogeneous series of models tha
Techno Trends
New Approach to Manipulating GPCRs
Gproteincoupled receptors or GPCRs are the most important signalling mechanism in human cells They react on exposure to the nutrients toxins hormones and light particles The major blockbuster drugs target the GPCRs for treatment of many diseases including heart disease cancer diabetes depression and arthritis These drugs affect GPCRs behaviour external to the cells Re...
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Demystifying Lead-time bias and Length-time bias in Clinical Trials
Jefry Winner G has completed his MBBS from Vinayaka Missions Medical College. He is currently pursuing a Doctorate of Medicine in Pharmacology at JIPMER Puducherry. He is interested in clinical research and is currently involved in an academic clinical trial involving Epilepsy. He has four years of clinical experience in healthcare and Academia. His area of interest includes Clinical trials, Pharmacotherapeutics, Drug safety, and clinical pharmacology. He also has over 15 publications in peer-reviewed journals.
Nanotechnology based Drug Delivery for Infectious Diseases
Dr. Vinod Kumar Rajana, Assistant Professor of Pharmaceutics, specializes in nanotechnology, bioassays, and infectious disease research. With expertise in nanoparticle synthesis, biotechnology, and drug delivery, his work integrates green chemistry with pharmaceutical innovation to develop sustainable, low-cost nanomaterials for topical antifungal and anticancer therapies, water purification, and biomedical applications.
The Green Revolution in Medicine
Dr Aishwarya Jain is an Assistant Professor and award-winning pharmaceutical researcher recognised with over 70+ national and international honours. Her research focuses on green synthesis, nanotechnology, and sustainable drug delivery. A SCOPUS journal editor and published author, she is dedicated to advancing eco-friendly pharmaceutical innovation and inspiring the next generation of researchers.
Harnessing Artificial Intelligence
Anita-Ioana Visan, a Scientific Researcher 2nd degree, at the Laser-Surface-Plasma Interactions (LSPI) Laboratory, Lasers Department, National Institute for Lasers, Plasma and Radiation Physics (INFLPR) in Magurele, is an expert in nanopowders synthesis and characterisation, as well as thin coatings of calcium phosphates, biopolymers, flavonoids, antibiotics, and antimicrobial peptides synthesized by Pulsed Laser Deposition, Matrix Assisted Pulsed Laser Evaporation, and Combinatorial-MAPLE. Moreover, she has a profound knowledge of thin films characterisation methods, including UV-Vis, FTIR, XRD, SEM, AFM, fluorescence microscopy, electrochemical, magnetic induction, biodegradation, and antimicrobial tests. With her current research focusing on the cutting-edge fields of artificial neural networks, drug repurposing, and pharmaceutical AI, she is paving the way for innovative solutions that have the potential to revolutionise the field of medicine. If you would like to contact her, please use the following email address: anita.visan@inflpr.ro. Furthermore, you can find her professional profile at https://orcid.org/0000-0003-0539-4160.
Irina Negut is a Scientific Researcher 2nd degree, at the National Institute for Lasers, Plasma and Radiation Physics (INFLPR) in Magurele, Romania. She has important experience in fabricating and investigating the characteristics and (bio) functionality of nano-sized/-structured materials (including composite and hybrid particles, thin films and laser-processed coatings). Her research activity includes coating synthesis by laser-assisted techniques. She is also highly experienced in evaluating the compositional and microstructural aspects of nanomaterials and coatings, but also in assessing their optical, thermal, electrical, and electrochemical properties. If you would like to contact her, please use the following email address: negut.irina@inflpr.ro. Her professional profile can be found at https://orcid.org/0000-0003-4038-7548.
Peptide-Drug Conjugates in Precision Oncology
Dr. Keykavous Parang is a professor at Chapman University with expertise in peptide-based therapeutics and targeted drug delivery systems. He has published extensively in bioconjugate chemistry and nanomedicine, focusing on translating innovative molecular platforms into clinically viable cancer treatments.
Thuy Do is a Pharm.D. student at Chapman University School of Pharmacy with research interests in nanomedicine and cancer therapeutics. She is involved in Dr. Parang’s capstone project, focusing on peptide-based conjugates and nanoparticle drug delivery systems for the development of innovative targeted cancer treatments.
Clare Dinh ('27) is a second-year PharmD student at Chapman University with a leadership emphasis. Active in various professional organizations, she is passionate about pharmaceutical research and plans to pursue postgraduate residency or fellowship programs to further her professional career.
Mahsa Moazen is a PharmD student at Chapman University and a researcher in Dr. Parang’s peptide drug conjugates project. She earned her bachelor’s degree in Pharmaceutical Chemistry. Her academic interests focus on peptide conjugates for targeted cancer therapy, bridging pharmaceutical research and clinical practice to advance innovative drug development.”
Troy Khong is a PharmD student at Chapman University School of Pharmacy, set to graduate with a Pharm.D. with a Leadership Degree Emphasis in 2027. I am excited to continue growing in the field of pharmacy and look forward to pursuing opportunities related to pharmaceutical industry.
press releasesRead more...
Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven Discovery
As AI accelerates recombinant protein and antibody discovery for therapeutic and diagnostic development access to wellcharacterized target proteins is essential for evaluating AIdesigned molecules Sino Biological Inc Shenzhen Stock Exchange SZ a global biotechnology company
Collaboration aims to accelerate development of next generation medicines
The Personalised Medicine Centre PMC a joint initiative between Murdoch University and the Perron Institute biotechnology company Syngenis Labs and the Perron Institute are collaborating to establish a specialised preclinical safety testing platform for RNAbased medicines designed to treat diseases...
ITM and AtomVie Global Radiopharma Enter Supply Agreement for n.c.a. Lutetium-177
ITM Isotope Technologies Munich SE ITM a leading radiopharmaceutical biotech company and AtomVie Global Radiopharma AtomVie a radiopharmaceutical contract development and manufacturing organization CDMO today announced a supply agreement
Evotec and Bristol Myers Squibb advance strategic protein degradation partnership with second IND acceptance
Evotec SE NASDAQ EVO Frankfurt Prime Standard EVT today announced that its strategic protein degradation partnership with Bristol Myers Squibb has received a second Investigational New Drug IND acceptance from the US Food
Introducing Cognizant® Patient Hub Operations: AI-enabled patient access offering designed to shorten the path from prescription to therapy
Cognizant Nasdaq CTSH today introduced Cognizant Patient Hub Operations an offering built on NVIDIA accelerated computing that pairs AI agents with healthcareexperienced specialists to support patients and help drive better access to therapy
Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production
Thermo Fisher Scientific the world leader in serving science today announced the Gibco VaxEvo CD Medium a chemically defined and animal originfree medium designed to support suspension HEK cell growth and hightiter adenovirus production
EventsRead more...
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
03 - 04
Dec 2026Pharmacy and Pharmaceutical Conference
Madrid, Spain
03 - 04
Dec 2026Infectious and Rare Diseases
Paris, France
LATEST NEWSRead more...
Bionsight Enters into Collaboration with Astellas to Develop Autoimmune Disorder Therapy
Bionsight has entered into a global research and development RD collaboration with Astellas Pharma to explore a potential firstinclass treatment for autoimmune disorders
Isomorphic Labs Enters into Collaboration with MSD for Cancer Drug Discovery
Isomorphic Labs has entered into a strategic research collaboration with MSD to discover smallmolecule drug candidates for an important oncology target
Sanofi Receives Approval for Infilbray to Treat Neurological Symptoms of Type 3 Gaucher Disease
Sanofi has received approval from the US Food and Drug Administration FDA for Infilbray venglustat an oral medicine for treating neurological manifestations of Type Gaucher disease GD in adults and children weighing at least kg
Pfizer Enters into Agreement with Starna Therapeutics for Autoimmune Disease Treatments
Pfizer has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics to develop RNAbased in vivo chimeric antigen receptor Tcell CART therapies for autoimmune diseases
OXB Partners with Aura Biosciences for Drug Manufacturing
OXB has confirmed a manufacturing and supply partnership with Aura Biosciences
GSK Receives Approval for Nelkarmi to Treat Advanced ALK-Positive Lung Cancer
GSK plc LSENYSE GSK has received accelerated approval from the US Food and Drug Administration FDA for Nelkarmi neladalkib a treatment for adults with locally advanced or metastatic anaplastic lymphoma kinase ALKpositive nonsmall cell lung cancer NSCLC


